Literature DB >> 16041160

Combination of heart-type fatty acid binding protein and brain natriuretic peptide can reliably risk stratify patients hospitalized for chronic heart failure.

Takeshi Niizeki1, Yasuchika Takeishi, Takanori Arimoto, Tatsuya Takahashi, Hidenobu Okuyama, Noriaki Takabatake, Naoki Nozaki, Osamu Hirono, Yuichi Tsunoda, Tetsuro Shishido, Hiroki Takahashi, Yo Koyama, Akira Fukao, Isao Kubota.   

Abstract

BACKGROUND: The aim of the present study was to prospectively study whether a combination of markers for myocardial cell injury and left ventricular overload at admission can reliably risk stratify patients hospitalized for chronic heart failure (CHF). METHODS AND
RESULTS: Serum concentrations of heart-type fatty acid binding protein (H-FABP) and plasma concentrations of brain natriuretic peptide (BNP) were measured at admission in 186 consecutive patients hospitalized for CHF. During a mean follow-up period of 534+/-350 days, there were 44 cardiac events, including 16 cardiac deaths and 28 readmissions for worsening heart failure. Normal upper limits for H-FABP and BNP values were determined from the receiver operating characteristic curves (4.3 ng/ml for H-FABP and 200 pg/ml for BNP). A stepwise Cox regression analysis demonstrated that high H-FABP (hazard ratio 5.416, p = 0.0002) and high BNP (hazard ratio 2.411, p = 0.0463) were independent predictors of cardiac events. High concentrations of both H-FABP and BNP at admission were associated with the highest incidence of cardiac mortality and cardiac events. Kaplan-Meier analysis also showed that the combination of H-FABP and BNP concentrations could reliably stratify patients for cardiac events.
CONCLUSION: Combined measurement of H-FABP and BNP concentrations at admission may be a highly reliable evaluation for risk stratifying patients hospitalized for CHF.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16041160     DOI: 10.1253/circj.69.922

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  15 in total

1.  The relationship among brain natriuretic peptide (BNP), cholesterol and lipoprotein.

Authors:  Hidekazu Takeuchi; Masataka Sata
Journal:  Heart Asia       Date:  2012-01-01

2.  Serum Level of Heart-Type Fatty Acid Binding Protein (H-FABP) Before and After Treatment of Congestive Heart Failure in Children.

Authors:  Amr Zoair; Wegdan Mawlana; Amany Abo-Elenin; Mostafa Korrat
Journal:  Pediatr Cardiol       Date:  2015-06-30       Impact factor: 1.655

Review 3.  Novel and potential future biomarkers for assessment of the severity and prognosis of chronic heart failure : a clinical review.

Authors:  David R Buvat de Virginy
Journal:  Heart Fail Rev       Date:  2006-12       Impact factor: 4.214

4.  Increased H-FABP concentrations in nonalcoholic fatty liver disease. Possible marker for subclinical myocardial damage and subclinical atherosclerosis.

Authors:  O Başar; E Akbal; S Köklü; Y Tuna; E Koçak; N Başar; D Tok; H Erbiş; M Senes
Journal:  Herz       Date:  2013-01-18       Impact factor: 1.443

Review 5.  Biomarkers in heart failure: a clinical review.

Authors:  J Paul Rocchiccioli; John J V McMurray; Anna F Dominiczak
Journal:  Heart Fail Rev       Date:  2008-12-03       Impact factor: 4.214

6.  Electrocardiographic left ventricular hypertrophy Cornell product is a feasible predictor of cardiac prognosis in patients with chronic heart failure.

Authors:  Yoichiro Otaki; Hiroki Takahashi; Tetsu Watanabe; Shinpei Kadowaki; Taro Narumi; Yuki Honda; Hiromasa Hasegawa; Shintaro Honda; Akira Funayama; Satoshi Nishiyama; Takanori Arimoto; Tetsuro Shishido; Takehiko Miyashita; Takuya Miyamoto; Isao Kubota
Journal:  Clin Res Cardiol       Date:  2013-12-01       Impact factor: 5.460

7.  High sensitive troponin T and heart fatty acid binding protein: novel biomarker in heart failure with normal ejection fraction? A cross-sectional study.

Authors:  Wilfried Dinh; Werner Nickl; Reiner Füth; Mark Lankisch; Georg Hess; Dietmar Zdunek; Thomas Scheffold; Michael Coll Barroso; Klaus Tiroch; Dan Ziegler; Melchior Seyfarth
Journal:  BMC Cardiovasc Disord       Date:  2011-07-05       Impact factor: 2.298

8.  Association of heart-type fatty acid-binding protein with cardiovascular risk factors and all-cause mortality in the general population: the Takahata study.

Authors:  Yoichiro Otaki; Tetsu Watanabe; Hiroki Takahashi; Atushi Hirayama; Taro Narumi; Shinpei Kadowaki; Yuki Honda; Takanori Arimoto; Tetsuro Shishido; Takuya Miyamoto; Tsuneo Konta; Yoko Shibata; Akira Fukao; Makoto Daimon; Yoshiyuki Ueno; Takeo Kato; Takamasa Kayama; Isao Kubota
Journal:  PLoS One       Date:  2014-05-21       Impact factor: 3.240

9.  Association of the Aspartate Aminotransferase to Alanine Aminotransferase Ratio with BNP Level and Cardiovascular Mortality in the General Population: The Yamagata Study 10-Year Follow-Up.

Authors:  Miyuki Yokoyama; Tetsu Watanabe; Yoichiro Otaki; Hiroki Takahashi; Takanori Arimoto; Tetsuro Shishido; Takuya Miyamoto; Tsuneo Konta; Yoko Shibata; Makoto Daimon; Yoshiyuki Ueno; Takeo Kato; Takamasa Kayama; Isao Kubota
Journal:  Dis Markers       Date:  2016-10-31       Impact factor: 3.434

10.  Heart-type fatty acid binding protein and high-sensitivity troponin T are myocardial damage markers that could predict adverse clinical outcomes in patients with peripheral artery disease.

Authors:  Yoichiro Otaki; Hiroki Takahashi; Tetsu Watanabe; Gensai Yamaura; Akira Funayama; Takanori Arimoto; Tetsuro Shishido; Takuya Miyamoto; Isao Kubota
Journal:  BBA Clin       Date:  2015-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.